Data on this page show the responses of all individuals aged 12 years and older who received the adult 30 microgram formulation of the Pfizer COVID-19 vaccine and completed an AusVaxSafety survey sent on day 3 after vaccination. Safety data for individuals aged 5-11 years who received the paediatric 10 microgram formulation of the Pfizer COVID-19 vaccine are available here. These data provide you with a profile of what to expect in the days following your Pfizer COVID-19 vaccination and can assist when planning for your COVID-19 vaccination.

AusVaxSafety has reaffirmed the safety of these vaccines. Data on this page will no longer be updated. Find out more here.


The profile of reported events from AusVaxSafety surveillance of the Pfizer (Comirnaty) COVID-19 vaccine is similar to that reported in clinical trials and from post-marketing surveillance overseas.

AusVaxSafety's active vaccine safety surveillance system complements the TGA's enhanced safety surveillance activities. Find out more about how the TGA monitors the safety of COVID-19 vaccines and how you can report side effects on the TGA website.

Read more about how AusVaxSafety is conducting national COVID-19 vaccine safety surveillance in Australia here.

Links to further information on the expected profile for the Pfizer (Comirnaty) COVID-19 vaccine are available below: 

AusVaxSafety will continue to closely monitor the safety data of COVID-19 vaccines in use in Australia in conjunction with the TGA.

Last updated March 2023